Beinaglutide, a short-acting GLP-1RA with 100% homology to human GLP-1 [6], was approved by the State Drug Administration of China for glycaemic control in adults with type 2 diabetes or adult weight management. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.